Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Galmed Pharmaceuticals Ltd. (GLMD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/02/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ As previously disclosed, Galmed Pharmaceuticals Ltd. entered into a definitive agreement for a $1.5 million equity investment in OnKai Inc. in exchange for series seed preferred shares of OnKai. Previously and in addition to the foregoing, on January 5, 2023 the Company invested $1.5 million in OnKai through a Simple Agreement for Future Equity whic...",
"Consent of Brightman Almagor Zohar & Co",
"Audited Consolidated Financial Statements as of December 31, 2022 and for the year ended December 31, 2022 of OnKai",
"Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022 of OnKai" |
|
| 07/21/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/18/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/18/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 07/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On July 14, 2023, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The press release attached as Exhibit 99.1 to this Form 6-K is incorporated by reference into the...",
"Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering TEL AVIV, Israel, July 14, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant . The gross proceeds of the Offering to the Company, before placement agent fees and estimated offering expenses, are expected to be approximately $7.0 million. Each warrant is immediately exercisable for one ordinary share at an exercise price of $1.25 per ordinary share and will ..." |
|
| 07/13/2023 |
F-1/A
| Form F-1/A - Registration statement for certain foreign private issuers: [Amend] |
| 07/12/2023 |
F-1/A
| Form F-1/A - Registration statement for certain foreign private issuers: [Amend] |
| 07/10/2023 |
6-K
| Quarterly results |
| 06/16/2023 |
F-1
| Form F-1 - Registration statement for certain foreign private issuers: |
| 06/01/2023 |
6-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. , which includes the Compan...",
"Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results TEL AVIV, Israel, June 1, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023. Recent Developments ● Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis , a rare disease for which there is no approved treatment; ● Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University; ● Formed a strategic partnership with Onkai, Inc., leading an investment round of $6 millio..." |
|
| 05/12/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/11/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On May 9, 2023, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis .” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The first and third parag...",
"Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis The clinical research and development program will be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University. TEL AVIV, Israel, May 9, 2023 /PRNewswire/ — Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis . PSC is a chronic cholestatic liver disease, characterized by progressive and multifocal fibrosis of the biliary system, which typically results..." |
|
| 05/04/2023 |
6-K
| Quarterly results |
| 05/04/2023 |
6-K
| Quarterly results |
| 03/29/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.9% stake in Galmed Pharmaceuticals Ltd. |
| 02/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/07/2023 |
SC 13G/A
| Baharaff Allen reports a 17.3% stake in Galmed Pharmaceuticals Ltd. |
| 01/05/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On January 4, 2023, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The first, second, thir...",
"Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol ● Histological improvement in fibrosis was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant , a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases reported today full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters. The study enrolled 157 subjects with biopsy-proven NASH randomized 1:1:1 into three groups differing in the timing of the post-baseline liver biopsy . Fifty-one subjects underwent post-baseline biopsies prior to study discontinuation . Fibroscan ..." |
|
| 12/14/2022 |
6-K
| Quarterly results |
| 11/16/2022 |
6-K
| Quarterly results |
| 08/04/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results TEL AVIV, Israel, August 4, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis, and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022. Recent Developments ● Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications. ● Implementing a cost reduction plan that includes reduction in headcount and full-time ..." |
|
| 07/07/2022 |
6-K
| Quarterly results |
| 07/01/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/29/2022 |
6-K
| Quarterly results |
| 06/22/2022 |
6-K
| Quarterly results |
| 06/17/2022 |
6-K
| Quarterly results |
| 05/17/2022 |
6-K
| Quarterly results |
| 05/17/2022 |
6-K
| Quarterly results |
|
|
|